Evidence map›Paper›PMID 37382752›Full record

ReviewDiscover nano2023

Immobilized nanoparticles-mediated enzyme therapy; promising way into clinical development.

Ali Rajabi Zangi, Ala Amiri, Fatemeh Borzouee, Rafieh Bagherifar, Pouya Pazooki, Hamed Hamishehkar, Yousef Javadzadeh

Open access · diamondAbstract readReview
In one paragraph

Review in Discover nano, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.1field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 11 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Review
  5. Review
  6. Review
  7. Article
  8. Review
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 5 institutions in 1 country.

Ali Rajabi ZangiStudent Research Committee, Tabriz University of Medical Sciences, Tabriz, Iran.
Ala AmiriDepartment of Biotechnology, Faculty of Biological Sciences, Alzahra University, Tehran, Iran.
Fatemeh BorzoueeDepartment of Clinical Biochemistry, School of Pharmacy and Pharmaceutical Sciences, Isfahan University of Medical Sciences, Isfahan, Iran.
Rafieh BagherifarStudent Research Committee, Tabriz University of Medical Sciences, Tabriz, Iran.
Pouya PazookiCellular and Molecular Biology Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Hamed HamishehkarDrug Applied Research Center, Tabriz University of Medical Science, Tabriz, 5166-15731, Iran.
Yousef JavadzadehBiotechnology Research Center, and Faculty of Pharmacy, Tabriz University of Medical Science, Tabriz, 5166-15731, Iran. javadzadehy@yahoo.com.
Tabriz University of Medical Sciences · IRAlzahra University · IRIsfahan University of Medical Sciences · IRShahid Beheshti University of Medical Sciences · IRUniversity of Tabriz · IR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Enzyme (Enz)-mediated therapy indicated a remarkable effect in the treatment of many human cancers and diseases with an insight into clinical phases. Because of insufficient immobilization (Imb) approach and ineffective carrier, Enz therapeutic exhibits low biological efficacy and bio-physicochemical stability. Although efforts have been made to remove the limitations mentioned in clinical trials, efficient Imb-destabilization and modification of nanoparticles (NPs) remain challenging. NP internalization through insufficient membrane permeability, precise endosomal escape, and endonuclease protection following release are the primary development approaches. In recent years, innovative manipulation of the material for Enz immobilization (EI) fabrication and NP preparation has enabled nanomaterial platforms to improve Enz therapeutic outcomes and provide low-diverse clinical applications. In this review article, we examine recent advances in EI approaches and emerging views and explore the impact of Enz-mediated NPs on clinical therapeutic outcomes with at least diverse effects.

Indexed as

Clinical developmentDelivery systemEnzymeImmobilizationNanoparticles

Identifiers

PMID37382752
PMCPMC10409955
OpenAlexW4360610953

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.